Lytix Biopharma AS (LYTIX.OL) Stock Analysis & AI Equity Report
Lytix Biopharma AS (LYTIX.OL) overview
Lytix Biopharma AS (LYTIX.OL) stock analysis and AI equity research. For the latest completed financial year, 2024, Lytix Biopharma AS reported revenue of NOK 11.1m and operating profit of NOK -95.9m; the year-end share price was 5.88 NOK and market capitalisation was NOK 318m. Lytix Biopharma AS is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Lytix Biopharma AS's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-12-12. Data will be refreshed during report generation.
About Lytix Biopharma AS
Lytix Biopharma is a clinical-stage biotechnology company developing oncolytic molecule immunotherapies for cancer. Its lead candidate, ruxotemitide (LTX-315), is being studied as an intratumoral treatment in melanoma and other solid tumors, while LTX-401 remains in preclinical development. The company focuses on therapies designed to stimulate immune responses against tumors.
Generate the Lytix Biopharma AS report
Lytix Biopharma AS is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Lytix Biopharma AS and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.